1-(4-methoxy-2,3,6-trimethylphenyl)sulfonyl-N-methyl-N-(1-methylpiperidin-4-yl)-2,3-dihydroindole-3-carboxamide | 583813-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(4-methoxy-2,3,6-trimethylphenyl)sulfonyl-N-methyl-N-(1-methylpiperidin-4-yl)-2,3-dihydroindole-3-carboxamide
• CAS: 583813-27-8
• 化学式: C₂₆H₃₅N₃O₄S
• 分子量: 485.648
• InChiKey: CDODPCDVFQGXAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3-dihydro-1H-indole-3-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide 、 4-甲氧基-2,3,6-三甲基苯磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-(4-methoxy-2,3,6-trimethylphenyl)sulfonyl-N-methyl-N-(1-methylpiperidin-4-yl)-2,3-dihydroindole-3-carboxamide
  参考文献：
  名称：

  The discovery and SAR of indoline-3-carboxamides—A new series of 5-HT6 antagonists

  摘要：

  Antagonists of the 5-HT6 receptor have been shown to improve cognitive function in a wide range of animal models and as such may prove to be attractive agents for the symptomatic treatment of cognitive disorders such as Alzheimer's disease ( AD) and schizophrenia. We report herein the identification and SAR around N-(2-aminoalkyl)-1-(arylsulfonyl)indoline-3-carboxamides-a novel chemotype of 5-HT6 antagonists. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.085

文献信息

• 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
  申请人：Spinks Daniel

  公开号：US20050154023A1

  公开（公告）日：2005-07-14

  The present invention relates to 1-arylsulfonyl-3-substituted indole or indoline derivatives having the general formula I wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R 6 -R 11 , are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

  本发明涉及具有一般式I的1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物，其中虚线表示可选键；n为0或1；m为0-5，而Ar、R6-R11在说明中定义。本发明还涉及包含所述衍生物的制药组合物，并且涉及使用这些1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、抑郁症、神经系统疾病、认知增强、帕金森病、肌萎缩性侧索硬化症、阿尔茨海默病和亨廷顿病。
• Extended tethering approach for rapid identification of ligands
  申请人：Erlanson A. Daniel

  公开号：US20050186630A1

  公开（公告）日：2005-08-25

  The invention concerns a method for rapid identification and characterization of binding partners for a target molecule, and for providing binding partners with improved binding affinity. More specifically, the invention concerns an improved tethering method for the rapid identification of at least two binding partners that bind near one another to a target molecule.

  该发明涉及一种快速鉴定和表征目标分子的结合伙伴，并提供具有改进结合亲和力的结合伙伴的方法。更具体地说，该发明涉及一种改进的束缚方法，用于快速鉴定至少两个结合伙伴，这些结合伙伴靠近目标分子。
• 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：N.V. Organon

  公开号：EP1476151B1

  公开（公告）日：2008-07-16
• US7838518B2
  申请人：——

  公开号：US7838518B2

  公开（公告）日：2010-11-23
• The discovery and SAR of indoline-3-carboxamides—A new series of 5-HT6 antagonists
  作者：Mark Reid、Ian Carlyle、Wilson L. Caulfield、Tom R. Clarkson、Fiona Cusick、Ola Epemolu、Robert Gilfillan、Richard Goodwin、David Jaap、Elise C. O’Donnell、Jeremy Presland、Zoran Rankovic、Daniel Spinks、Gayle Spinks、Anne M. Thomson、Fiona Thomson、James Strain、Grant Wishart

  DOI：10.1016/j.bmcl.2010.04.085

  日期：2010.6

  Antagonists of the 5-HT6 receptor have been shown to improve cognitive function in a wide range of animal models and as such may prove to be attractive agents for the symptomatic treatment of cognitive disorders such as Alzheimer's disease ( AD) and schizophrenia. We report herein the identification and SAR around N-(2-aminoalkyl)-1-(arylsulfonyl)indoline-3-carboxamides-a novel chemotype of 5-HT6 antagonists. (C) 2010 Elsevier Ltd. All rights reserved.